Disposable Biopharmaceutical Processes–Myth or Reality? - - BioPharm International

ADVERTISEMENT

Disposable Biopharmaceutical Processes–Myth or Reality?


BioPharm International


Keith DiBlasi is the manager of technical services, Sartorius North America, Inc., Edgewood, NY. Maik W. Jornitz is the group vice president of bioprocess biosystems. Uwe Gottschalk, PhD, is the group vice president of purification technologies, Sartorius AG, Goettingen, Germany. Paul M. Priebe is head of product management process, Edgewood, NY.

References

1. Sinclair A, Monge M. Quantitative economic evaluation of single use disposables in bioprocessing. Pharmaceutical Eng. 2002;22: 20–34.

2. Prashad M, Tarrach K. Depth filtration aspects for the clarification of CHO cell derived biopharmaceutical feed streams. FISE. 2006;9:28–30.

3. Mora J, Sinclair A, Delmdahl N, Gottschalk U. Disposable membrane chromatography: performance analysis and economic cost model. BioProcess Int. 2006;4:38–43.

4. Zhou JX, Tressel T. Membrane chromatography as a robust purification system for large scale antibody production. BioProcess Int.2005; 3: 32–37.

5. Zhou JX, Tressel T. Basic concepts in Q membrane chromatography for large-scale antibody production. Biotechnol Progr. 2006;22:341–9.

6. Ransohoff T. Disposable Chromatography: Current Capabilities and Future Possibilities. BPD North Carolina Biotechnology Center, 2004 Nov 18.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines
Source: BioPharm International,
Click here